{"id":9059,"date":"2022-07-20T13:11:00","date_gmt":"2022-07-20T11:11:00","guid":{"rendered":"https:\/\/czecrin.cz\/project\/kh-kdo_dc1311\/"},"modified":"2026-01-06T09:50:48","modified_gmt":"2026-01-06T08:50:48","slug":"kh-kdo_dc1311","status":"publish","type":"project","link":"https:\/\/czecrin.cz\/en\/project\/kh-kdo_dc1311\/","title":{"rendered":"CT KDO_DC1311"},"content":{"rendered":"\n

CLINICAL TRIAL WHO_DC1311<\/h3>\n\n\n\n
\n\n\n\n
<\/div>\n\n\n\n

Combination anti-tumour therapy with ex vivo manipulated interleukin-12 producing dendritic cells in paediatric, adolescent and young adult patients with progressive, relapsed or primary metastatic high-risk malignancies<\/em><\/p>\n\n\n\n

KDO_DC1311 is a phase I\/II clinical trial to evaluate the safety and efficacy of a dendritic cell-based drug in pediatric, adolescent and young adult cancer patients.<\/p>\n\n\n\n

The medicinal product was developed and is manufactured by the CZECRIN GMP unit of ACIU MU. The drug is based on the patient’s own immune cells and a sample of the patient’s own tumour tissue. In the laboratories, a certain type of the sampled immune cells is allowed to mature and “learns” to recognise the sampled tumour cells. After administration of these ‘trained’ cells, the patient’s own anti-tumour defences should be boosted. <\/p>\n\n\n\n

The commissioner of the study is Masaryk University. Patients participating in the study are under the care of the principal investigating physician, Mr. MUDr. Peter M\u00fadr\u00fd, Ph.D. and his colleagues from the Department of Paediatric Oncology, University Hospital Brno. In parallel with the investigational drug, patients undergo all available anti-cancer treatment. <\/p>\n\n\n\n

OVERVIEW OF RECRUITMENT<\/h6>\n\n\n\n

Recruitment for the KDO_DC1311 study has been completed. Enrolled patients continue to be seen at the Clinical Paediatric Oncology Unit and their health status and disease progression is monitored. <\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n
<\/div>\n\n\n\n

Important links to the project<\/h2>\n\n\n\n
\n\n\n\n
<\/div>\n\n\n\n
EU Clinical Trials Register<\/a><\/strong><\/td>Publication Fedorova et al., Front Oncol 2019<\/a><\/strong><\/td><\/tr>
The publication by Hlavackova et. al, Front Oncol 2019 <\/a><\/strong><\/td>Personalized dendritic cell vaccine in multimodal individualized combination therapy…, RESEARCH ARTICLE<\/a><\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n
<\/div>\n\n\n\n

Project documents<\/h2>\n\n\n\n
\n\n\n\n
<\/div>\n\n\n\n
Approval of KH <\/a>S<\/a>UKL<\/a><\/strong><\/td>Approval of KH EK FN Brno<\/a><\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n
<\/div>\n\n\n\n
<\/div>\n\n\n\n
Contact<\/h5>\n\n\n\n

ctc.czecrin@med.muni.cz<\/a><\/p>\n\n\n\n

<\/div>\n\n\n\n